netFormulary NHS
NHS NEL
Demonstration Formulary
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
Link   NICE CG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Link   NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Link   NICE TA138: Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over
Link   NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
Link   BCICB Asthma Treatment Guidelines - Adolescents 12-17 years old
Link   BCICB Asthma Treatment Guidelines - Adults 18+
Link   BCICB Asthma Treatment Guidelines For Children Under 12
Link   BCICB COPD Inhaler Treatment Guidelines
Link   BCICB Difficult Asthma Referral Pathway - Adults 18+
Link   Greener Inhaler Guide Switching Information
Link   How to improve respiratory control in asthma and COPD
Link   COVID-19: information for the respiratory community
 Details...
03.11  Expand sub section  Antifibrotics
NintedanibBlack Triangle (Ofev®)
View adult BNF View SPC online View childrens BNF 		Restricted Drug Restricted
Red
NHS England

Hospital only- NHSE commissioned

In line with NICE and available from day 91 following publication of TA

 
Link  NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
 
Nintedanib (Vargatef®)
View adult BNF View SPC online View childrens BNF 		Formulary
Red
High Cost Medicine
NHS England

Hospital ONLY

NHSE comissioned

In line with NICE and available from day 91 following publication of TA

 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
 
Pirfenidone (Esbriet®)
View adult BNF View SPC online View childrens BNF 		Restricted Drug Restricted
Red
NHS England

Hospital only - NHSE commissioned

 
Link  NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
 
 ....
Key
Restricted Drug Restricted Drug
Unlicensed Drug Unlicensed
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
ICB
 ICB
Green Low Carbon

Low carbon footprint
Amber Medium Carbon

Medium carbon footprint
Red High carbon footprint

High carbon footprint
Status Description

Green

 Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications  

Amber Initiation

 Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.  

Amber SC

 Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.  

Amber Recommended

 Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.  

Red

 Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only  

Grey

 Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.  

Black

 Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.  

Multiple

 Check Notes as varies across the area  

netFormulary